Skip to Navigation

研究活動及び成果

home > 探索研究 > 研究活動及び成果

主要研究分野

出版物

Publications list
1 The therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricemia and gout. EULAR (The European League Against Rheumatism) Congress, 2013
2 Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. J Med Chem, 2012, 55, 7828
3 9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors. J Med Chem, 2011, 54, 6286
4 Newly discovered orally active pure antiestrogens. Bioorganic & Medicinal Chemistry Letters , 16, 4959-4964, 2006.
5 Discovery of thiochroman derivatives bearing a carboxy-containing side chain as orally active pure antiestrogens. Bioorganic & Medicinal Chemistry Letters , 16, 4090-4094, 2006.
6 Discovery of thiochroman and chroman derivatives as pure antiestrogens and their structure-activity relationship. Bioorganic & Medicinal Chemistry, 14, 4803-4819, 2006.
7 Role of aspartate 351 in transactivation and active conformation of estrogen receptor α. J. of Mol. Endocrinol., 35, 449-464, 2005.
8 Rapid Screening of Drug Absorption Potential Using Immobilized Artificial Membrane Phosphatidylcholine Column and Molar Volume. Chromatographia, 60, 399-404, 2004.
9 Evaluation of KCB-328, a new Ikr blocking antiarrhythmic agent in pacing induced canine arterial fibrillation. Europace, 6, 384-391, 2004
10 Differential Recovery of Action Potential Duration and HERG Currents from the Effects of Two Methanesulfonamide Class Ⅲ Antiarrhythmic Agents, KCB-328 and Dofetilide, Journal of Cardiovascular Pharmacology, 42(5), 648-655, 2003.
11 Ikr Channel Blockers: Novel Antiarrhythmic Agents. Curr. Med. Chem.-Cardiovascular & Hematological Agents, 1(3), 203-223, 2003.
12 The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis. Thrombosis and Haemostasis, 86(6), 1512-1520, 2001.
13 Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter. J. Cardiovasc Pharmacol Ther., 6(3), 297-306, 2001
14 In Vitro and In Vivo Studies of AT-1362, A Newly Synthesized and Orally Active Inhibitor of Thrombin. Thrombosis Research, 100(1), 97-107, 2000.
15 Clofilium, a potassium channel blocker, induces apoptosis of human promyelocyte leukemia(HL-60) cells via Bcl-2-insensitive activation of caspase-3. Cancer Letters, 147(1-2), 85-93, 1999.
16 Synthesis and Biological Activity of KCB-328 and its Analogues: Novel Class III Antiarrhythmic Agents with Little Reverse Frequency Dependence. Bioorganic & Medicinal Chemistry Letters, 9:85-90, 1999.
17 Studies on the New Factor on the Regulation of Contraction in the Balloon Injured Rabbit Carotid Artery. Kor. J. Gerontol, 8(1), 67-76, 1998.
18 KCB-328: A Novel Class III Antiarrhythmic Agent with Little Reverse Frequency Dependence in Isolated Guinea-Pig Myocardium. Journal of Cardiovascular Pharmacology, 31(4), 609-617, 1998.
19 Cloning and Nucleotide Sequence of the DNA Gyrase gyrA Gene from Serratia marcescens and Characterization of Mutations in gyrA of Quinolone-Resistant Clinical Isolates. Antimicrobial Agents and Chemotherapy, 42(1), 190-193, 1998.
20 Effects of a new class III antiarrhythmic drug, KCB-328 on canine arrhythmic models. The Japanese Journal of Pharmacology, 71(suppl I), 138, 1996.
21 Electrophysiological effects of KCB-328. A novel Class III antiarrhythmic agent in vitro. The FASEB Journal, 10(3), A32, 1996.
22 Frequency-dependent effects of KCB-328. A novel Class III antiarrhythmic agent in isolated guinea pig ventricular muscle. The FASEB Journal, 10(3), A32, 1996.
23 Role of aspartate 351 in transactivation and active conformation of estrogen receptor α. J. of Mol. Endocrinol., 35, 449-464, 2015.
24 Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis. J Med Chemm, 2018, 61(7), 2949

研究成果

2017

  • FR-1345 アトピー治療剤
    JW Pharmaceuticalにライセンスアウト

2010

  • URC-102 通風治療剤
    日本の中外製薬(株)と韓国のJW Pharmaceutical Co.に
    ライセンスアウト
    臨床2相へ開始(2014)

2001

  • 乳がん治療剤
    臨床開発物質ライセンスアウト
  • 過敏性腸症候群治療剤
    臨床開発物質ライセンスアウト